Roche’s efforts to break into the lucrative obesity market haven’t abated. The pharma giant sealed the largest deal in the space earlier this year when it announced a collaboration with Zealand Pharma ...

Investing.com -- Wells Fargo (NYSE: WFC) has initiated coverage of Zealand Pharma (NASDAQ: ZEAL) with an Overweight rating ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

The latest round of terminations, which will take effect Sept. 15, comes after Genentech fired more than 500 employees in the ...

Roche and Zealand Pharma have formed a potential $5.3 billion collaboration to bring amylin analog petrelintide to market as an obesity treatment, both on its own and in combination with Roche's ...